This AJMRR Clinical Study highlights the successful application of Presigen IV in reducing intraocular pressure in 87% of trial participants, marking a significant breakthrough in glaucoma management. The clinical framework presented is robust, with a focus on personalized medicine, ocular inflammation biomarkers, and nutrient-based modulation.